Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • The AASLD/IDSA (Management Guidelines)[AASLD-IDSA HCV] and EASL (Management Guidelines)[EASL HCV] guideline panels provide recommendations for the use of DAA regimens in the treatment of HCV infection in patients with recurrent HCV infection in posttransplantation settings (Table 13)
  • Treatment of HCV should be initiated for recurrent liver disease based either on persistent, unexplained elevated ALT levels or on histologically confirmed fibrosis once rejection, biliary obstruction, and vascular damage have been ruled out (Table 14)[Ghany 2009; Ponziani 2011]
  • Drug–drug interactions between HCV therapies and immunosuppressants commonly prescribed in the posttransplantation setting may occur (Table 14)

    Action required

    Keywords: Hepatitis C, Hepatitis C-Posttransplant Management, Hepatitis C-Special Populations

    ©2018 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.